Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Improvements in overall survival have been observed with the introduction of rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), however, prognostic markers ar...
Main Authors: | , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259438/ |